X4 Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences

BOSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting from dysfunction of the CXCR4 pathway, today announced that management will conduct one-on-one investor meetings at the Citi 16th Annual BioPharma Conference and participate in a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference.

Details are as follows:

Conference: Citi 16th Annual BioPharma ConferenceDate: September 8 – 10, 20211x1 meetings only

Conference: H.C. Wainwright 23rd Annual Global Investment ConferenceDate: Monday, September 13, 2021Time: 7:00 AM ETFireside Chat Webcast Link

A live webcast of the H.C. Wainwright 23rd Annual Global Investment Conference fireside chat will be available on the investor section of the X4 Pharmaceuticals website at www.x4pharma.com. The event will remain archived on the X4 Pharmaceuticals’ website for approximately 90 days.

About X4 PharmaceuticalsX4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases of the immune system resulting from dysfunction of the CXCR4 pathway, with a focus on rare diseases and those with limited treatment options. The company’s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy. X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer. The efficacy and safety of mavorixafor, dosed once daily, is currently being evaluated in a number of clinical trials, including a global Phase 3 clinical trial in patients with WHIM syndrome, and in two Phase 1b clinical trials – in combination with ibrutinib in patients with Waldenström’s macroglobulinemia, and as monotherapy in patients with Severe Congenital Neutropenia and other chronic neutropenia disorders. X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Boston, Massachusetts and at its research facility in Vienna, Austria, and is discovering and developing additional product candidates. For more information, please visit www.x4pharma.com.

Investors and Media: Daniel FerryManaging Director LifeSci Advisors[email protected](617) 430-7576

Mónica Rouco MolinaSenior Account Executive LifeSci Communications[email protected]

You May Also Be Interested In

• American Fusion Inc. (OTCQB: AMFN) Reaches Major Intellectual Property Milestone with 100 Patent Applications Pending
• Data on debtor composition
• Lookthrough and BuildingMinds Join Forces to Build the Leading AI Platform for Real Estate Decision Intelligence